News Kadcyla finally gets OK after price cut and NICE concessions Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE.
News Puma gains as Roche breast cancer combo disappoints ASCO serves up shock as Roche's data disappoints
News ASCO round up: Zytiga shines in frontline prostate role, Lox... While ASCO often showcases the benefits of new cancer therapies, it was a well-established drug that proved to be a talking point at this year’s conference in Chicago.
News AZ highlights data from next-gen oncology drugs at ASCO Tesara and Takeda among other companies to publish data.
News FDA advisers back Puma breast cancer drug despite safety wor... But biotech still has several hurdles to clear - including Roche's rival.
News Waiting on NICE decision, Pfizer provides breast cancer drug... NICE rejected Ibrance in initial decision in February.
News Halozyme abandons its €2bn pursuit of Evotec Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been unwilling to engage with negotiations
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
